Merck KGaA (also called as the Merck Group), branded and commonly known as Merck, is a German multinational pharmaceutical, chemical and life sciences company headquartered in Darmstadt, with about 56,000 employees and present in 66 countries. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies in the world.
Merck operates in Europe, Africa, Asia, Oceania and the Americas. It has major research and development centres in Darmstadt, Boston, Tokyo and Beijing. Merck pioneered the commercial manufacture of morphine in the 19th century and for a time held a virtual monopoly on cocaine.
Merck was privately owned until going public on the Frankfurt Stock Exchange in 1995, and is listed on the DAX index of Germany's top companies. The Merck family still controls a majority 70.3% of the company's shares. The Merck Group includes around 250 companies in 180 countries; the current main parent company of the group, since 1995, is named Merck KGaA, and is itself mainly owned by the former main parent company, E. Merck oHG, which now operates as a holding company.
The American pharmaceutical company Merck & Co. was established as a subsidiary of Merck in 1891, but was nationalized by the United States in 1917, before being privatized again when George W. Merck purchased back the stock in 1919. It is known as MSD (Merck Sharp and Dohme) outside of North America. The original Merck of Darmstadt holds the rights to the name Merck in all countries except the U.S. and Canada, where it is known as EMD (Emanuel Merck, Darmstadt). In 2015 Merck adopted a new uniform brand identity for all its subsidiaries, and the company has stressed its intention to protect the brand of "the real Merck" globally and initiated litigation against its former subsidiary over use of the name.
Allergan plc is an Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.
In 2016, Allergan sold its generic business, Actavis, to Teva for $40.5 billion.
In June 2019, U.S. pharmaceutical company AbbVie announced it had reached an agreement to acquire Allergan for $63 billion. The merged company would be domiciled in the U.S. for tax purposes.
mAbxience is a biotechnology company specialized in the research, development and manufacture of biosimilar monoclonal antibodies, part to the pharmaceutical Insud Pharma Group. Set up in 2009, it currently has two facilities for development and production, in Spain and Argentina. In December 2014, it launched its first biosimilar, rituximab, which is now approved and distributed in many markets globally. Its second product, bevacizumab, was launched in its first market in November 2016.
In mAbxience we develop the highest quality biosimilars through our state-of-the-art development and analytical platform.
Our work methodology is our identity.
With a strong development platform and four production sites, AMEGA Biotech develops and produces biosimilars. Exporting recombinant proteins worldwide and focused on central markets registrations, AMEGA Biotech is the leading regional producer.
Our work and vision are directed forward. Our production model is based on a comprehensive design and integration of all the processes involved in the production of high quality and high technology products. This competitive advantage allows us to face the present and future challenges of a dynamic field.
We contribute to the future of biotechnology by understanding its high impact on society and its benefits on human health.
Krka’s basic line of business is the production and sale of prescription pharmaceuticals, non-prescription products and animal health products.
The company's focus is on the development of high-quality own-brand generic pharmaceuticals, which offer added value, and are marketed under Krka's own brands.
Living a healthy life.
Our basic task is to enable people to lead a healthy, good quality life. This we achieve through our rich range of products and services – with prescription pharmaceuticals, self-medication products, with cosmetic and animal health products, and with our health-resort services, with investment in people and the environment, and through sponsorship and donations.
continually consolidating our position as one of the leading generic
pharmaceutical companies worldwide.
We are achieving this on our own by strengthening the long-term business connections and by establishing partnerships in the fields of development, product supply and marketing.
Speed and flexibility
Our knowledge, our abilities, our capability to innovate, our
productivity and our ingenuity enable us to be fast. We want to be first. Not
just in sales, but in discovering the markets’ new needs. We can do this by
successfully shortening the development process, swift acquisition of
registration documentation and our harmonised production and distribution.
With our responsiveness and the ability to adapt we overcome the obstacles in our path, be they of a marketing or legislative nature. We can cope with any and all challenges – regardless of the size and the site of the project. Using flexible solutions, we make sure our partners can rely on us.
Partnership and trust
Krka helps create good relationships. We strive for trust-based relationships with our partners: our customers, our suppliers, our owners and everyone else who surrounds us. Only good and open relationships can help us achieve both business success and our primary mission.
Creativity and efficiency
The only real way to achieve first-class results is by creating
an atmosphere that motivates our employees to be innovative and creative.
Therefore, we encourage our employees to speak freely of their ideas and if
these ideas prove to be good for the company, we encourage them realise them.
Together, we seek new paths to make our customers satisfied.
We perform our tasks as well as we can. We strive to do what we do in the best, most efficient and most time conserving way.
Laboratorios Rubió was founded in 1968 by SALVADOR AND PELAYO RUBIÓ, with the goal of selling medication that at that time were not available on the market in this country, since they were treatments for low prevalence diseases that did not attract anyone’s attention. Both brothers, pharmacists by profession, left the traditional pharmacy behind in order to create an innovative company, inspired by a clear vocation to serve society. With an extraordinary ability to understand what a healthcare professional needs in order to better perform their work and care for their patients, the Rubió brothers were pioneers in marketing calcium polystyrene sulfonate, a new drug to treat hyperkalaemia, which became the company’s first big success.
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS. Backed by over 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, Generics, Biosimilars, Custom Pharmaceutical services and Branded Generics. The company is globally recognized for its strengths in Research and Development, manufacturing and commercialization of a wide range of products.
Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, audited and approved by stringent regulatory authorities like US FDA, EU, TGA-Australia, MCC-South Africa and others. Our portfolio includes 300 plus products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology, Urology, Diabetes, Ophthalmology, Hepatology and Immunology etc.
Hetero has a strong global presence in over 126 countries and focusses on making affordable medicines accessible to patients worldwide.
At Hetero, quality is one factor we cherish greatly and we make every effort to sustain it at every level. The approvals from stringent global regulatory authorities for our manufacturing facilities bear testimony to this claim.
And each of our manufacturing facility is state-of-the-art with integrated quality systems and processes which facilitate absolute compliance with cGMP (current Good Manufacturing Practices).
Quality control labs equipped with high-precision equipment ensure that excellence is maintained consistently throughout the production processes. Also, the highest standards are adhered to when it comes to health, safety and environmental practices.
Chemo is part of the Spanish multinational, INSUD PHARMA, a group with a strong foundation and a firm investor commitment to all our business activity areas. With 40 years’ of experience, INSUD PHARMA is a group that aims to sustain and improve people’s health and wellbeing, and has a presence at every echelon of the chemical-pharmaceutical industry. Its activities are carried out through three synergistic business areas: industrial, branded and biotechnology. Insud Pharma has a presence in more than 40 countries in Europe, the Americas, Asia and Africa, and is backed up by a network of more than 6,000 professionals.
Over 1,000 clients among top pharmaceutical companies worldwide, CHEMO holds a position of leading company in industry, developing and manufacturing added-value active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs), both for human and animal health, in all mayor therapeutics (Cardiovascular, Gastroenterology, Central Nervous System, Anti-infective, Respiratory, Women`s Healthcare, Endocrinology, Dermatology and Urology).